Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 17.67%19.98B | -1.94%18.79B | -16.31%17.71B | -3.70%76.41B | -6.25%19.11B | -17.27%16.98B | 2.62%19.16B | 7.05%21.16B | 20.25%79.34B | 12.99%20.38B |
Cost of revenue | 15.44%16.83B | -7.13%15.74B | -15.70%15.27B | 1.64%65.01B | -10.95%15.38B | -16.14%14.58B | 14.58%16.94B | 24.76%18.11B | 23.91%63.96B | 19.65%17.27B |
Gross profit | 31.18%3.15B | 37.80%3.05B | -19.95%2.44B | -25.92%11.39B | 19.77%3.73B | -23.50%2.4B | -42.94%2.21B | -41.92%3.05B | 7.10%15.38B | -13.66%3.12B |
Operating expense | 3.85%1.7B | 0.73%1.67B | -5.12%1.61B | 1.34%6.65B | -1.89%1.66B | 0.00%1.64B | -1.14%1.65B | 8.90%1.7B | 10.79%6.56B | 10.32%1.69B |
Staff costs | ---- | ---- | ---- | -8.24%1.68B | ---- | ---- | ---- | ---- | 6.08%1.83B | ---- |
Selling and administrative expenses | ---- | ---- | ---- | 1.62%1.81B | ---- | ---- | ---- | ---- | 2.41%1.79B | ---- |
-Selling and marketing expense | ---- | ---- | ---- | -22.54%165M | ---- | ---- | ---- | ---- | -5.33%213M | ---- |
-General and administrative expense | ---- | ---- | ---- | 4.90%1.65B | ---- | ---- | ---- | ---- | 3.56%1.57B | ---- |
Research and development costs | ---- | ---- | ---- | 12.88%631M | ---- | ---- | ---- | ---- | 58.36%559M | ---- |
Other operating expenses | ---- | ---- | ---- | 5.79%2.52B | ---- | ---- | ---- | ---- | 13.64%2.38B | ---- |
Operating profit | 90.01%1.45B | 147.06%1.39B | -38.65%827M | -46.20%4.75B | 45.41%2.08B | -49.20%761M | -74.59%561M | -63.44%1.35B | 4.50%8.82B | -31.33%1.43B |
Net non-operating interest income (expenses) | 3.13%-93M | -31.43%-92M | -26.39%-91M | -3.11%-332M | -27.03%-94M | -23.08%-96M | 16.67%-70M | 16.28%-72M | 6.40%-322M | 11.90%-74M |
Non-operating interest income | 0.00%55M | 9.43%58M | 10.00%55M | 30.67%213M | 14.58%55M | 27.91%55M | 39.47%53M | 47.06%50M | 20.74%163M | 41.18%48M |
Non-operating interest expense | -1.99%148M | 21.95%150M | 19.67%146M | 12.37%545M | 22.13%149M | 24.79%151M | 0.82%123M | 1.67%122M | 1.25%485M | 3.39%122M |
Net investment income | -164.29%-37M | -74.73%47M | 1.79%57M | -44.25%281M | 173.61%53M | -110.37%-14M | 186M | 56M | 62.06%504M | -162.07%-72M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 0 | 0 | 487.50%517M | 0 | 0 | 132.88%340M | 177M | 125.64%88M | -58M |
Income from associates and other participating interests | 102.94%11M | -107.35%-141M | 21.27%-618M | -198.27%-1.87B | -3,688.89%-646M | -145.44%-374M | -111.43%-68M | -267.02%-785M | 954.71%1.91B | -95.67%18M |
Special income (charges) | 114.58%28M | 34.38%-84M | -134.91%-249M | 25.63%-383M | 150.59%43M | 21.95%-192M | -3.23%-128M | -76.67%-106M | 62.82%-515M | 81.11%-85M |
Less:Other special charges | -114.58%-28M | -34.38%84M | 134.91%249M | -25.63%383M | -150.59%-43M | -21.95%192M | 3.23%128M | 76.67%106M | -43.59%515M | -80.68%85M |
Other non-operating income (expenses) | -1,300.00%-72M | -83.51%16M | -45.16%17M | 103.23%2M | -20.00%-132M | -25.00%6M | 504.17%97M | -51.56%31M | 90.96%-62M | -46.67%-110M |
Income before tax | 1,308.79%1.28B | 23.29%1.13B | -108.98%-58M | -71.66%2.95B | 24.38%1.3B | -95.75%91M | -70.90%919M | -84.15%646M | 69.46%10.42B | -48.82%1.04B |
Income tax | 179.80%277M | 13.71%282M | -52.48%259M | -158.01%-1.42B | -527.91%-2.32B | -59.59%99M | -61.90%248M | -46.36%545M | 250.86%2.45B | 123.74%541M |
Net income | 12,662.50%1.01B | 26.64%851M | -417.00%-317M | -45.04%4.38B | 622.20%3.61B | -100.42%-8M | -73.20%672M | -96.73%100M | 2.43%7.96B | -88.41%500M |
Net income continuous operations | 12,662.50%1.01B | 26.83%851M | -413.86%-317M | -45.05%4.38B | 620.76%3.61B | -100.42%-8M | -73.23%671M | -96.70%101M | 2.44%7.96B | -88.39%501M |
Noncontrolling interests | 0 | 0 | 0 | 0 | 0 | 0 | 300.00%12M | 100.00%2M | ||
Net income attributable to the company | 14,457.14%1.01B | 26.83%851M | -417.00%-317M | -44.96%4.38B | 623.65%3.61B | -100.37%-7M | -73.15%671M | -96.73%100M | 2.33%7.95B | -88.43%499M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 14,457.14%1.01B | 26.83%851M | -417.00%-317M | -44.96%4.38B | 623.65%3.61B | -100.37%-7M | -73.15%671M | -96.73%100M | 2.33%7.95B | -88.43%499M |
Gross dividend payment | ||||||||||
Basic earnings per share | 18,400.00%7.32 | 27.52%6.21 | -417.81%-2.32 | -41.54%31.83 | 606.18%26.27 | -100.31%-0.04 | -71.37%4.87 | -96.50%0.73 | 2.91%54.45 | -87.33%3.72 |
Diluted earnings per share | 14,448.72%7.32 | 27.28%6.1985 | -417.81%-2.32 | -41.54%31.83 | 636.19%26.27 | -100.40%-0.051 | -71.37%4.87 | -96.50%0.73 | 2.91%54.45 | -87.85%3.5684 |
Dividend per share | 0 | 33.33%4 | 0 | -47.06%9 | -33.33%6 | 0 | -62.50%3 | 0 | 6.25%17 | -25.00%9 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |